ArticleBMC cancer2010
Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Assessment of Dried Plasma Spots (DPS) as an Appropriate Sample Matrix for the Measurement of Circulating Calretinin, a Biomarker for Mesothelioma-A Proof-Of-Concept Study.Journal of clinical laboratory analysis · 2026Article
- Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.International journal of molecular sciences · 2023Article
- Article
- Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.Journal of clinical medicine · 2023Review
- Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review.Sensors (Basel, Switzerland) · 2021Review
- Serum Calretinin as a Biomarker in Malignant Mesothelioma.Journal of clinical medicine · 2021Article
- Article
- Determinants of plasma calretinin in patients with malignant pleural mesothelioma.BMC research notes · 2020Article
- Article
- Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.Scientific reports · 2018Article
- Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.International journal of medical sciences · 2018Article
- Article
- Calretinin as a blood-based biomarker for mesothelioma.BMC cancer · 2017Article
- Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.Disease markers · 2017Article
- Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Scientific reports · 2016Article
- Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Cancer science · 2015Article
- Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.PloS one · 2014Article
- Article
- Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions.Annals of clinical biochemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalretinin is one of the well-established immunohistochemical markers in the diagnostics of malignant mesothelioma (MM). Its utility as a diagnostic tool in human blood, however, is scarcely investigated. The aim of this study was to develop an enzyme-linked immunosorbent assay (ELISA) for human calretinin in blood and to assess its usefulness as a potential minimally invasive diagnostic marker for MM.
methodsInitially, attempts were made to establish an assay using commercially available antibodies and to optimize it by including a biotin-streptavidin complex into the assay protocol. Subsequently, a novel ELISA based on polyclonal antibodies raised in rabbit immunized with human recombinant calretinin was developed. The assay performance in human serum and plasma (EDTA/heparin) and the influence of calcium concentrations on antibody recognition were studied. Stability of spiked-in calretinin in EDTA plasma under different storage conditions was also examined. In preliminary studies serum and plasma samples from 97 healthy volunteers, 35 asbestos-exposed workers, and 42 MM patients were analyzed.
resultsThe mean detection range of the new ELISA was 0.12 to 8.97 ng/ml calretinin. The assay demonstrated markedly lower background and significantly higher sensitivity compared to the initially contrived assay that used commercial antibodies. Recovery rate experiments confirmed dependence of calretinin antibody recognition on calcium concentration. Calcium adjustment is necessary for calretinin measurement in EDTA plasma. Spiked-in calretinin revealed high stability in EDTA plasma when stored at room temperature, 4 degrees C, or after repeated freeze/thaw cycles. Median calretinin values in healthy volunteers, asbestos workers, and MM patients were 0.20, 0.33, and 0.84 ng/ml, respectively (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for asbestos-exposed vs. MM). Median values in patients with epithelioid and biphasic MM were similar. No influence of age, gender, smoking status, or type of medium (plasma/serum) on calretinin values was found.
conclusionsThe novel assay is highly sensitive and applicable to human serum and plasma. Calretinin appears to be a promising marker for the blood-based detection of MM and might complement other markers. However, further studies are required to prove its usefulness in the diagnosis of MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.